October 11, 2023
Open to all ISPOR Members and Non-members
Title: How Does Biosimilar Availability Create Value for the Patient? A Conversation About Avenues to Widen Access to Biologics
Wednesday, October 11, 2023
10:00AM EDT | 2:00PM UTC | 4:00PM CEST
Click here for time zone conversion
The emergence of biologics has revolutionized cancer care, as well as the treatment of immune-mediated inflammatory conditions, but it has also been an important driver of pharmaceutical spending. The high cost of biological therapies has therefore resulted in treatment inequalities between patients. The entrance of biosimilars into clinical practice has led to a decrease in biological treatment costs.
Beyond cost savings, biosimilar adoption has also demonstrated delivering value for public health improvement, such as widening patients’ access to biologics and quality of care improvements. After 17 years of biosimilar availability in Europe, and clinical experience with biosimilars exceeding two billion patient treatment days, it is of interest to reflect on how biosimilar entrance creates value for the patient.
The aim of this webinar is to discuss real-life examples on how biosimilar adoption has positively impacted care and patient access to biological therapies, focusing on testimonies from patient, policy, and healthcare professional representatives. Speakers are invited to converse on what the tangible benefits are that biosimilars have delivered for patients, and how biosimilar availability has supported access to care and the implementation of optimized disease management initiatives. The webinar will conclude with a moderated debate on what is needed to further increase the value proposition from biosimilar entry for patients. Topics of interest for the audience will be further addressed as part of the Q&A session.
- To gain knowledge from real-life examples on how biosimilar adoption has positively impacted care
- To integrate testimonies from patient, policy, and healthcare professional representatives on the topic of biosimilar value
- To reflect on what is further needed to increase the value proposition from biosimilar entry for patients
Moderator:
Teresa Barcina, MSc, PharmD, PhD Student, Health Economics, KU Leuven University, Leuven, Belgium
Speakers:
Liese Barbier, MSc, PharmD, PhD, Postdoctoral Researcher, KU Leuven, Leuven, Belgium
Zorana Maravic, MBA, CEO, Digestive Cancers Europe, Belgrade, Serbia
Peter Taylor, MA, PhD, FRCP, FRCPE, Norman Collisson Professor of Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford University, Oxford, England, UK
Lindsay Keir, MBChB, PhD, Director, Science and Policy Advisory Team, Policy Cures Research, London, England, UK
Brought to you by: ISPOR Biosimilars Special Interest Group
Please note: On the day of the scheduled webinar, the first 1000 registered participants will be accepted into the webinar. For those who are unable to attend, or would like to review the webinar at a later date, the full-length webinar recording will be made available at the ISPOR Educational Webinar Series webpage approximately 2 days after the scheduled Webinar.